# EDGAR Filing Document

**Accession Number:** 0001649094
**File Stem:** 0001193125-26-067521
**Filing Date:** 2026-2
**Character Count:** 28221
**Document Hash:** 7376efd0f0b8d2d5252caece8594e05a
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-26-067521.hdr.sgml**: 20260224

**ACCESSION NUMBER**: 0001193125-26-067521

**CONFORMED SUBMISSION TYPE**: S-8

**PUBLIC DOCUMENT COUNT**: 14

**FILED AS OF DATE**: 20260224

**DATE AS OF CHANGE**: 20260224

**EFFECTIVENESS DATE**: 20260224

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Vaxcyte, Inc.
- **CENTRAL INDEX KEY:** 0001649094
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 464233385
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** S-8
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 333-293704
- **FILM NUMBER:** 26672969

**BUSINESS ADDRESS:**
- **STREET 1:** 825 INDUSTRIAL ROAD, STE. 300
- **CITY:** SAN CARLOS
- **STATE:** CA
- **ZIP:** 94070
- **BUSINESS PHONE:** 650-837-0111

**MAIL ADDRESS:**
- **STREET 1:** 825 INDUSTRIAL ROAD, STE. 300
- **CITY:** SAN CARLOS
- **STATE:** CA
- **ZIP:** 94070

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** SutroVax, Inc.
- **DATE OF NAME CHANGE:** 20150724

**As filed with the Securities and Exchange Commission on February 24, 2026** 

**Registration No. 333-** 

**UNITED STATES** 

**SECURITIES AND EXCHANGE COMMISSION** 

**Washington, D.C. 20549** 

**FORM S-8** 

**REGISTRATION STATEMENT** 

***UNDER***

***THE SECURITIES ACT OF 1933***

## VAXCYTE, INC.
**(Exact name of registrant as specified in its charter)** 

---

| | |
|:---|:---|
| **Delaware** | **46-4233385** |
| **(State or other jurisdiction of**<br> **Incorporation or organization)** | **(I.R.S. Employer**<br> **Identification No.)** |

---

**825 Industrial Road, Suite 300** 

**San Carlos, California 94070** 

**(Address of principal executive offices) (Zip code)** 

**2020 Equity Incentive Plan** 

**(Full titles of the plans)** 

**Grant E. Pickering** 

**Chief Executive Officer** 

**Vaxcyte, Inc.** 

**825 Industrial Road, Suite 300** 

**San Carlos, California 94070** 

**(650) 837-0111** 

**(Name and address of agent for service) (Telephone number, including area code, of agent for service)** 

***Copies to:***

**Michael J. Hong** 

**Skadden, Arps, Slate, Meagher & Flom LLP** 

**One Manhattan West** 

**New York, New York 10001** 

**Telephone: (212) 735-3000**

**Facsimile: (212) 735-2000**

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

---

| | | | |
|:---|:---|:---|:---|
| Large accelerated filer | ☒ | Accelerated filer | ☐ |
| Non-accelerated filer | ☐ | Smaller reporting company | ☐ |
|  |  | Emerging growth company | ☐ |

---

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

------

**EXPLANATORY NOTE** 

Vaxcyte, Inc. (the "***Registrant***") is filing this Registration Statement on Form S-8 for the purpose of registering (a) 6,552,942 shares of its Common Stock issuable to eligible persons under the Registrant's 2020 Equity Incentive Plan, which Common Stock is in addition to the shares of Common Stock registered on the Registrant's Registration Statements on Form S-8 filed on June 12, 2020 (File No.[333-239135](http://www.sec.gov/Archives/edgar/data/0001649094/000119312520167697/d944834ds8.htm)), March 29, 2021 (File No.[333-254824](http://www.sec.gov/Archives/edgar/data/1649094/000156459021016130/pcvx-s8.htm)), February 28, 2022 (File No.[333-263093](http://www.sec.gov/Archives/edgar/data/1649094/000119312522058075/d295369ds8.htm)), February 27, 2023 (File No.[333-270064](http://www.sec.gov/Archives/edgar/data/1649094/000119312523050907/d390124ds8.htm)), February 27, 2024 (File No.[333-277413](http://www.sec.gov/Archives/edgar/data/1649094/000119312524048062/d750221ds8.htm)) and February 25, 2025 (File No.[333-285216](http://www.sec.gov/Archives/edgar/data/1649094/000119312525035211/d916489ds8.htm)) (together, the "***Prior Registration Statements***"), and (b) 1,310,588 shares of its Common Stock issuable under the Registrant's 2020 Employee Stock Purchase Plan, which Common Stock is in addition to the shares of Common Stock registered on the Prior Registration Statements.

------

**PART II** 

---

| | |
|:---|:---|
| **ITEM 3.** | **INCORPORATION OF CERTAIN DOCUMENTS BY REFERENCE**  |

---

Pursuant to General Instruction E to Form S-8, the contents of the Prior Registration Statements are incorporated by reference herein. The Registrant hereby incorporates by reference into this Registration Statement the following documents filed by it with the Securities and Exchange Commission (the "***SEC***"):

(a) the Registrant's Annual Report on [Form 10-K](http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1649094/000164909426000007/pcvx-20251231.htm) for the year ended December 31, 2025, filed with the SEC on February 24, 2026; and

(b) The description of the Common Stock contained in the Registrant's Registration Statement on [Form 8-A](http://www.sec.gov/Archives/edgar/data/1649094/000119312520164625/d926263d8a12b.htm) (File No. 001-39323) filed with the SEC on June 9, 2020, as updated by [Exhibit 4.2](http://www.sec.gov/Archives/edgar/data/1649094/000156459021016110/pcvx-ex42_374.htm) to the Registrant's Annual Report on Form 10-K for the year ended December 31, 2020 and any amendments or reports filed for the purpose of updating such description.

All other reports and documents subsequently filed by the Registrant pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Securities Exchange Act of 1934, as amended (other than Current Reports furnished under Item 2.02 or Item 7.01 of Form 8-K and exhibits furnished on such form that relate to such items) on or after the date of this Registration Statement and prior to the filing of a post-effective amendment to this Registration Statement which indicates that all securities offered have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference herein and to be a part of this Registration Statement from the date of the filing of such reports and documents. Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or in any subsequently filed document that also is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.

------

---

| | |
|:---|:---|
| **ITEM 8.** | **EXHIBITS** |

---

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
|  |  | **Incorporated by Reference** | **Incorporated by Reference** | **Incorporated by Reference** | **Incorporated by Reference** |
| **Exhibit** | **Description** | **Schedule/**<br> **Form** | **File Number** | **Exhibits** | **Filing Date** |
| 4.1 | [Second Amended and Restated Certificate of Incorporation of Vaxcyte, Inc.](http://www.sec.gov/Archives/edgar/data/1649094/000164909426000007/exhibit31-secondarcertific.htm) | 10-K | 001-39323 | 3.1 | February 24, 2026 |
| 4.2 | [Amended and Restated Bylaws of Vaxcyte, Inc., as amended.](http://www.sec.gov/Archives/edgar/data/1649094/000095017023059395/pcvx-ex3_2.htm) | 10-Q | 001-39323 | 3.2 | November 6,<br>2023 |
| 4.3 | [Form of Pre-Funded Warrant.](http://www.sec.gov/Archives/edgar/data/1649094/000119312522008768/d259937dex41.htm) | 8-K | 001-39323 | 4.1 | January 13, 2022 |
| 4.4 | [Form of Pre-Funded Warrant.](http://www.sec.gov/Archives/edgar/data/1649094/000119312522270039/d374961dex41.htm) | 8-K | 001-39323 | 4.1 | October 27, 2022 |
| 4.5 | [Form of Pre-Funded Warrant.](http://www.sec.gov/Archives/edgar/data/1649094/000119312523106984/d490519dex41.htm) | 8-K | 001-39323 | 4.1 | April 20, 2023 |
| 4.6 | [Form of Pre-Funded Warrant.](http://www.sec.gov/Archives/edgar/data/1649094/000119312524021084/d752729dex41.htm) | 8-K | 001-39323 | 4.1 | January 31, 2024 |
| 4.7 | [Form of Pre-Funded Warrant.](http://www.sec.gov/Archives/edgar/data/1649094/000119312524214711/d802914dex41.htm) | 8-K | 001-39323 | 4.1 | September 6,<br>2024 |
| 5.1 | [Opinion of Skadden, Arps, Slate, Meagher & Flom LLP.](d36050dex51.htm) |  |  |  | X |
| 23.1 | [Consent of Independent Registered Public Accounting Firm.](d36050dex231.htm) |  |  |  | X |
| 23.2 | [Consent of Skadden, Arps, Slate, Meagher & Flom LLP (reference is made to Exhibit 5.1).](d36050dex51.htm) |  |  |  | X |
| 24.1 | [Power of Attorney (reference is made to the signature page hereto).](#sig) |  |  |  | X |
| 99.1 | [2020 Equity Incentive Plan.](http://www.sec.gov/Archives/edgar/data/1649094/000095017023039817/pcvx-ex10_1.htm) | 10-Q | 001-39323 | 10.1 | August 8, 2023 |
| 99.2 | [2020 Employee Stock Purchase Plan.](http://www.sec.gov/Archives/edgar/data/1649094/000119312520162659/d802328dex104.htm) | S-1/A | 333-238630 | 10.4 | June 8, 2020 |
| 99.3 | [Form of Stock Option Grant Notice and Stock Option Agreement.](http://www.sec.gov/Archives/edgar/data/1649094/000095017023039817/pcvx-ex10_2.htm) | 10-Q | 001-39323 | 10.2 | August 8, 2023 |
| 99.4 | [Form of Restricted Stock Unit Grant Notice.](http://www.sec.gov/Archives/edgar/data/1649094/000095017022008485/pcvx-ex10_2.htm) | 10-Q | 001-39323 | 10.2 | May 9, 2022 |
| 99.5 | [Form of Non-U.S. Stock Option Grant Notice and Stock Option Agreement.](http://www.sec.gov/Archives/edgar/data/1649094/000095017024021145/pcvx-ex10_26.htm) | 10-K | 001-39323 | 10.26 | February 27, 2024 |
| 99.6 | [Form of Non-U.S. Restricted Stock Unit Grant Notice.](http://www.sec.gov/Archives/edgar/data/1649094/000095017024021145/pcvx-ex10_27.htm) | 10-K | 001-39323 | 10.27 | February 27, 2024 |
| 99.7 | [Form of Performance Restricted Stock Unit Award Grant Notice and Agreement.](http://www.sec.gov/Archives/edgar/data/1649094/000164909425000074/pcvx-20250331exhibit101.htm) | 10-Q | 001-39323 | 10.1 | May 7, 2025 |
| 99.8 | [Form of Performance Contingent Stock Option Grant Notice and Agreement.](http://www.sec.gov/Archives/edgar/data/1649094/000164909425000074/pcvx-20250331exhibit102.htm) | 10-Q | 001-39323 | 10.2 | May 7, 2025 |
| 107 | [Filing Fee Table.](d36050dexfilingfees.htm) |  |  |  | X |

---

X Filed herewith.

------

**SIGNATURES** 

Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of San Carlos, State of California, on February 24, 2026.

---

| | |
|:---|:---|
| **VAXCYTE, INC.** | **VAXCYTE, INC.** |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;By: | /s/ Grant E. Pickering |
|  | **Grant E. Pickering** |
|  | **Chief Executive Officer** |

---

**POWER OF ATTORNEY** 

KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Grant E. Pickering and Andrew Guggenhime, and each of them, as his or her true and lawful attorneys-in-fact and agents, each with the full power of substitution, for him or her and in their name, place or stead, in any and all capacities, to sign any and all amendments to this Registration Statement (including post-effective amendments), and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents or any of them, or his, her or their substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement on Form S-8 has been signed by the following persons in the capacities and on the dates indicated.

------

---

| | | |
|:---|:---|:---|
| **Signature** | **Title** | **Date** |
| /s/ Grant E. Pickering<br> **Grant E. Pickering** | Chief Executive Officer and Director<br> *(Principal Executive Officer)* | February 24, 2026 |
| /s/ Andrew Guggenhime<br> **Andrew Guggenhime** | President and Chief Financial Officer<br> *(Principal Financial Officer)* | February 24, 2026 |
| /s/ Elvia Cowan<br> **Elvia Cowan** | Senior Vice President, Finance and<br> Chief Accounting Officer<br> *(Principal Accounting Officer)* | February 24, 2026 |
| /s/ Carlos Paya<br> **Carlos Paya, M.D., Ph.D.** | Director | February 24, 2026 |
| /s/ Olivier Brandicourt<br> **Olivier Brandicourt, M.D.** | Director | February 24, 2026 |
| /s/ Annie Drapeau<br> **Annie Drapeau** | Director | February 24, 2026 |
| /s/ John Furey<br> **John Furey** | Director | February 24, 2026 |
| /s/ Halley Gilbert<br> **Halley Gilbert** | Director | February 24, 2026 |
| /s/ Jacks Lee<br> **Jacks Lee** | Director | February 24, 2026 |
| /s/ Teri Loxam<br> **Teri Loxam** | Director | February 24, 2026 |
| /s/ Heath Lukatch<br> **Heath Lukatch, Ph.D.** | Director | February 24, 2026 |

---

## Exhibit 5.1

**Exhibit 5.1** 

---

| | |
|:---|:---|
| SKADDEN, ARPS, SLATE, MEAGHER & FLOM LLP |  |
| ONE MANHATTAN WEST |  |
| NEW YORK, NY 10001<br>——<br>TEL: (212) 735-3000<br> FAX: (212) 735-2000<br> **www**.skadden.com | FIRM/AFFILIATE<br> OFFICES |
| NEW YORK, NY 10001<br>——<br>TEL: (212) 735-3000<br> FAX: (212) 735-2000<br> **www**.skadden.com | —— |
| NEW YORK, NY 10001<br>——<br>TEL: (212) 735-3000<br> FAX: (212) 735-2000<br> **www**.skadden.com | BOSTON |
| NEW YORK, NY 10001<br>——<br>TEL: (212) 735-3000<br> FAX: (212) 735-2000<br> **www**.skadden.com | CHICAGO |
| NEW YORK, NY 10001<br>——<br>TEL: (212) 735-3000<br> FAX: (212) 735-2000<br> **www**.skadden.com | HOUSTON |
| NEW YORK, NY 10001<br>——<br>TEL: (212) 735-3000<br> FAX: (212) 735-2000<br> **www**.skadden.com | LOS ANGELES |
|  | PALO ALTO |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;February 24, 2026 | WASHINGTON, D.C. |
|  | WILMINGTON |
|  | ABU DHABI |
|  | BEIJING |
|  | BRUSSELS |
|  | FRANKFURT |
|  | HONG KONG |
|  | LONDON |
|  | MUNICH |
|  | PARIS |
|  | SÃO PAULO |
|  | SEOUL |
|  | SINGAPORE |
|  | TOKYO |
|  | TORONTO |

---

Vaxcyte, Inc.

825 Industrial Road, Suite 300

San Carlos, California 94070

RE: Vaxcyte, Inc.

<u>Registration Statement on Form S-8</u>

Ladies and Gentlemen:

We have acted as special United States counsel to Vaxcyte, Inc., a Delaware corporation (the "<u>Company</u>"), in connection with the registration statement on Form S-8 (together with the exhibits thereto, the "<u>Registration Statement</u>") to be filed on the date hereof by the Company with the Securities and Exchange Commission (the "<u>Commission</u>") under the Securities Act of 1933 (the "<u>Securities Act</u>"). The Registration Statement relates to the registration of (i) 6,552,942 shares (the "<u>Equity Incentive Plan Shares</u>") of the Company's common stock, par value $0.001 per share (the "<u>Common Stock</u>"), available for future issuance pursuant to the Vaxcyte, Inc. 2020 Equity Incentive Plan (the "<u>Equity Incentive Plan</u>") and (ii) 1,310,588 shares (the "<u>Stock Purchase Plan Shares</u>" and, together with the Equity Incentive Plan Shares, the "<u>Shares</u>") of the Common Stock, available for future issuance pursuant to the Vaxcyte, Inc. 2020 Employee Stock Purchase Plan (together with the Equity Incentive Plan, the "<u>Plans</u>").

This opinion letter is being furnished in accordance with the requirements of Item 601(b)(5) of Regulation S-K General Rules and Regulations of the Commission promulgated under the Securities Act (the "<u>Rules and Regulations</u>").

In rendering the opinion stated herein, we have examined and relied upon the following:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) the Plans;

------

Vaxcyte, Inc.

February 24, 2026

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) the Registration Statement in the form to be filed with the Commission on the date hereof;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) an executed copy of a certificate of Mikhail Eydelman, General Counsel and Secretary of the Company, dated the
date hereof (the " <u>Secretary's Certificate</u> ");

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) a copy of the Company's Certificate of Incorporation, certified by the Secretary of State of the State of
Delaware as of the dates the Plans were adopted, and certified pursuant to the Secretary's Certificate as being in effect as of the dates the Plans were adopted;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e) a copy of the Company's Second Amended and Restated Certificate of Incorporation (the " <u>Amended and Restated Certificate of Incorporation</u> "), certified by the Secretary of State of the State of Delaware as of February 23, 2026, and certified pursuant to the Secretary's Certificate as being in effect as of the date hereof

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f) a copy of the Company's Bylaws, as certified pursuant to the Secretary's Certificate as being in
effect as of the dates the Plans were adopted;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(g) a copy of the Company's Amended and Restated Bylaws (the " <u>Amended and Restated Bylaws</u> "), as amended and certified pursuant to the Secretary's Certificate as being in effect as of the date hereof;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(h) a copy of certain resolutions of the Board of Directors of the Company adopted on June 4, 2020, as
certified pursuant to the Secretary's Certificate;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) a copy of a certificate, dated the date hereof, from the Secretary of State of the State of Delaware with
respect to the Company's existence and good standing in the State of Delaware; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(j) the form of award agreements under the Plans.

We have also examined originals or copies, certified or otherwise identified to our satisfaction, of such records of the Company and such agreements, certificates and receipts of public officials, certificates of officers or other representatives of the Company and others, and such other documents as we have deemed necessary or appropriate as a basis for the opinion stated below.

In our examination, we have assumed the genuineness of all signatures, including electronic signatures, the legal capacity and competency of all natural persons, the authenticity of all documents submitted to us as originals, the conformity to original documents of all documents submitted to us as facsimile, electronic, certified or photocopied copies, and the authenticity of the originals of such copies. In making our examination of executed documents, we have assumed that the parties thereto, other than the Company, had the power, corporate or

------

Vaxcyte, Inc.

February 24, 2026

other, to enter into and perform all obligations thereunder and have also assumed the due authorization by all requisite action, corporate or other, and the execution and delivery by such parties of such documents and the validity and binding effect thereof on such parties. As to any facts relevant to the opinion stated herein that we did not independently establish or verify, we have relied upon statements and representations of officers and other representatives of the Company and others and of public officials, including the facts and conclusions set forth in the Secretary's Certificate and the Amended and Restated Certificate of Incorporation.

We do not express any opinion with respect to the laws of any jurisdiction other than the General Corporation Law of the State of Delaware (the "<u>DGCL</u>").

Based upon the foregoing and subject to the qualifications and assumptions stated herein, we are of the opinion that the Shares have been duly authorized by all requisite corporate action on the part of the Company under the DGCL and, when awarded by the Board of Directors of the Company or a duly authorized committee thereof and issued and paid for in accordance with the terms of the Plans and the award agreements under the Plans, the Shares will be validly issued, fully paid and nonassessable.

In rendering the opinion stated herein, we have assumed that (i) an appropriate account statement evidencing the Shares credited to a recipient's account maintained with the Company's transfer agent and registrar has been or will be issued by the Company's transfer agent and registrar; (ii) the issuance of the Shares will be properly recorded in the books and records of the Company; (iii) each award agreement pursuant to which rights to acquire Shares or other awards are granted pursuant to the Plans will be consistent with the Plans and will be duly authorized, executed and delivered by the parties thereto; (iv) the consideration received by the Company for each of the Shares delivered pursuant to the Plans shall not be less than the $0.001 per share; (v) the Company will continue to have sufficient authorized shares of Common Stock; (vi) the Company's issuance of the Shares does not and will not (a) except to the extent expressly stated in the opinion contained herein, violate any statute to which the Company or such issuance is subject, or (b) constitute a violation of, or a breach under, or require the consent or approval of any other person under any agreement or instrument binding on the Company (except that we do not and will not make this assumption with respect to the Amended and Restated Certificate of Incorporation and the Amended and Restated Bylaws, although we have assumed compliance with any covenant, restriction or provision with respect to financial ratios or tests or any aspect of the financial condition or results of operations of the Company contained in such instruments); (vii) the Company will continue to have sufficient authorized shares of Common Stock; and (viii) the Company's authorized capital stock is as set forth in the Amended and Restated Certificate of Incorporation and we have relied solely on the certified copy thereof issued by the Secretary of State of the State of Delaware and have not made any other inquiries or investigations.

------

Vaxcyte, Inc.

February 24, 2026

We hereby consent to the filing of this opinion letter with the Commission as an exhibit to the Registration Statement. In giving this consent, we do not thereby admit that we are within the category of persons whose consent is required under Section 7 of the Securities Act or the rules and regulations of the Commission thereunder. This opinion letter is expressed as of the date hereof unless otherwise expressly stated, and we disclaim any undertaking to advise you of any subsequent changes in the facts stated or assumed herein or of any subsequent changes in applicable laws.

---

| |
|:---|
| Very truly yours, |
| /s/ Skadden, Arps, Slate, Meagher & Flom LLP |

---

MJH

## Exhibit 23.1

**Exhibit 23.1** 

**CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM** 

We consent to the incorporation by reference in this Registration Statement on Form S-8 of our reports dated February 24, 2026 relating to the financial statements of Vaxcyte, Inc. and the effectiveness of Vaxcyte, Inc.'s internal control over financial reporting, appearing in the Annual Report on Form 10-K of Vaxcyte, Inc. for the year ended December 31, 2025.

/s/ Deloitte & Touche LLP

San Francisco, California

February 24, 2026

## Ex-Filing

?xml version='1.0' encoding='ASCII'? EX-FILING FEES

---

| |
|:---|
| **Calculation of Filing Fee Tables**  |
| &nbsp;&nbsp;&nbsp;&nbsp;**S-8**  |
| &nbsp;&nbsp;&nbsp;&nbsp;**Vaxcyte, Inc.**  |

---

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| | **Security Type**  | **Security Class Title**  | **Fee Calculation Rule**  | **Amount Registered**  | **Proposed Maximum Offering Price Per Unit**  | **Maximum Aggregate Offering Price**  | **Fee Rate**  | **Amount of Registration Fee**  |
| 1 | Equity | Common Stock, par value $0.001 per share, 2020 Equity Incentive Plan | Other | 6552942 | $53.96 | $353596750.32 | 0.0001381 | $48831.71 |
| 2 | Equity | Common Stock, par value $0.001 per share, 2020 Employee Stock Purchase Plan | Other | 1310588 | $53.96 | $70719328.48 | 0.0001381 | $9766.34 |
| Total Offering Amounts: | Total Offering Amounts: | Total Offering Amounts: | Total Offering Amounts: | Total Offering Amounts: |  | $424316078.80  |  | $58598.05  |
| Total Fee Offsets:  | Total Fee Offsets:  | Total Fee Offsets:  | Total Fee Offsets:  | Total Fee Offsets:  |  |  |  | $0.00  |
| Net Fee Due:  | Net Fee Due:  | Net Fee Due:  | Net Fee Due:  | Net Fee Due:  |  |  |  | $58598.05  |

---

 **Offering Note** <br>

<sup>1</sup> Pursuant to Rule 416(a) under the Securities Act of 1933, as amended (the "Securities Act"), this Registration Statement shall also cover any additional shares of common stock, par value $0.001 per share ("Common Stock"), of Vaxcyte, Inc. (the "Registrant") that become issuable by reason of any stock dividend, stock split, recapitalization or any other similar transaction effected without receipt of consideration which results in an increase in the number of outstanding shares of Common Stock. Estimated in accordance with Rules 457(c) and 457(h) solely for purposes of calculating the registration fee on the basis of $53.96, the average of the high and low prices of the Registrant's Common Stock as reported on The Nasdaq Global Stock Market on February 17, 2026. Represents an automatic annual increase to the shares of Common Stock reserved for issuance equal to 5% of the total number of shares of Common Stock outstanding on December 31 of the preceding calendar year, which annual increase is provided by the Registrant's 2020 Equity Incentive Plan.

<sup>2</sup> Pursuant to Rule 416(a) under the Securities Act of 1933, as amended (the "Securities Act"), this Registration Statement shall also cover any additional shares of common stock, par value $0.001 per share ("Common Stock"), of Vaxcyte, Inc. (the "Registrant") that become issuable by reason of any stock dividend, stock split, recapitalization or any other similar transaction effected without receipt of consideration which results in an increase in the number of outstanding shares of Common Stock. Estimated in accordance with Rules 457(c) and 457(h) solely for purposes of calculating the registration fee on the basis of $53.96, the average of the high and low prices of the Registrant's Common Stock as reported on The Nasdaq Global Stock Market on February 17, 2026. Represents an automatic annual increase to the shares of Common Stock reserved for issuance equal to 1% of the total number of shares of Common Stock outstanding on December 31 of the preceding calendar year, which annual increase is provided by the Registrant's 2020 Employee Stock Purchase Plan.

---

| | |
|:---|:---|
| | |
| **Rule 457(p)** | **Rule 457(p)** |
| Fee Offset Claims | N/A |
| Fee Offset Sources | N/A |

---